A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

July 31, 2009

Conditions
Hepatic Impairment
Interventions
DRUG

Phentermine and Topiramate

Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).

Trial Locations (2)

33014-3616

Clinical Pharmacology of Miami, Miami

32809-3017

Orlando Clinical Research Center, Orlando

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Covance

INDUSTRY

collaborator

Sentrx

INDUSTRY

lead

VIVUS LLC

INDUSTRY